Erudio Healtherudio.com
Drug
Sintilimab trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying sintilimab: LungTIME-C01. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LungTIME-C01 NCT05549037 · Hunan Province Tumor Hospital | advanced non-small cell lung cancer | Phase 3 | 237 | 70 | Standard | Oct 30, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ORIENT-31 NCT03802240 · Innovent Biologics (Suzhou) Co. Ltd. DeepView → | EGFR-mutated non-squamous NSCLC after EGFR-TKI treatment failure | Phase 3 | Deep | View | |||
| NCT05244798 NCT05244798 · Sichuan Cancer Hospital and Research Institute FocusedView → | locally advanced esophageal squamous cell carcinoma | Phase 3 | Focused | View | |||